These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The anamnestic antibody response to type 3 specific pneumococcal polysaccharide. Paul WE; Benacerraf B; Siskind GW; Goidl DA; Reisfeld RA J Exp Med; 1969 Jul; 130(1):77-89. PubMed ID: 4389341 [TBL] [Abstract][Full Text] [Related]
43. [Method of removing nonspecific hemagglutination inhibitors from diagnostic and postinfection sera]. Zakstel'skaia LIa; Shenderovich SF Vopr Virusol; 1979; (5):560-1. PubMed ID: 388865 [No Abstract] [Full Text] [Related]
44. Fractionation of antibodies to the pneumococcal polysaccharides by affinity chromatography. Cheng WC; Fraser KJ; Haber E J Immunol; 1973 Dec; 111(6):1677-89. PubMed ID: 4127299 [No Abstract] [Full Text] [Related]
45. Immunochemistry of the pneumococcal types II. V. and VI. I. The relation of Type VI to Type II and other correlations between chemical constitution and precipitation in antisera to type VI. HEIDELBERGER M; REBERS PA J Bacteriol; 1960 Aug; 80(2):145-53. PubMed ID: 14400599 [No Abstract] [Full Text] [Related]
46. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. Anttila M; Eskola J; Ahman H; Käyhty H J Infect Dis; 1998 Jun; 177(6):1614-21. PubMed ID: 9607841 [TBL] [Abstract][Full Text] [Related]
48. Quantitative studies of the specificity of anti-pneumococcal polysaccharide antibodies, types 3 and 8. 3. Binding of a labeled oligosaccharide derived from S8 by anti-S8 antibodies. Pappenheimer AM; Reed WP; Brown R J Immunol; 1968 Jun; 100(6):1237-44. PubMed ID: 4387095 [No Abstract] [Full Text] [Related]
52. Planning for a second (23 valent) generation pneumococcal vaccine. With special reference to new developments in our understanding of the structure and biology of polysaccharides. Robbins JB; Schneerson R Bull Eur Physiopathol Respir; 1983; 19(2):215-26. PubMed ID: 6347282 [TBL] [Abstract][Full Text] [Related]
54. [Protective activity of a cell-free Klebsiella vaccine in infection in mice caused by Streptococcus pneumoniae serotypes]. Kurbatova EA; Egorova NB; Krasnoproshina LI; Rodionychev EA; Mansurova NL Zh Mikrobiol Epidemiol Immunobiol; 1985 Feb; (2):60-5. PubMed ID: 3887815 [TBL] [Abstract][Full Text] [Related]
55. A new multiantigen immunoassay for the quantification of IgG antibodies to capsular polysaccharides of Streptococcus pneumoniae. Roth F; Burkart T; Mühlemann K J Infect Dis; 1997 Aug; 176(2):526-9. PubMed ID: 9237724 [TBL] [Abstract][Full Text] [Related]
57. [Emphasis on bacterial vaccines]. Huet M Arch Inst Pasteur Tunis; 1982 Dec; 59(4):481-93. PubMed ID: 6820928 [No Abstract] [Full Text] [Related]
58. New vaccines for prevention of pneumococcal infections. Eskola J; Käyhty H Ann Med; 1995 Feb; 27(1):53-6. PubMed ID: 7741999 [No Abstract] [Full Text] [Related]